Liaoning Chengda Biotechnology Stock Net Income
| 688739 Stock | 27.32 0.43 1.60% |
Liaoning Chengda Biotechnology fundamentals help investors to digest information that contributes to Liaoning Chengda's financial success or failures. It also enables traders to predict the movement of Liaoning Stock. The fundamental analysis module provides a way to measure Liaoning Chengda's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Liaoning Chengda stock.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 465.9 M | 590.2 M | |
| Net Income | 465.9 M | 590.2 M |
Liaoning | Net Income |
Liaoning Chengda Biotechnology Company Net Income Analysis
Liaoning Chengda's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Liaoning Chengda Net Income | 465.92 M |
Most of Liaoning Chengda's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Liaoning Chengda Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Liaoning Net Interest Income
Net Interest Income |
|
Based on the recorded statements, Liaoning Chengda Biotechnology reported net income of 465.92 M. This is 36.52% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all China stocks is 18.4% higher than that of the company.
Liaoning Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Liaoning Chengda's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Liaoning Chengda could also be used in its relative valuation, which is a method of valuing Liaoning Chengda by comparing valuation metrics of similar companies.Liaoning Chengda is currently under evaluation in net income category among its peers.
Liaoning Fundamentals
| Return On Equity | 0.0346 | ||||
| Return On Asset | 0.0239 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.37 % | ||||
| Current Valuation | 5.86 B | ||||
| Shares Outstanding | 416.45 M | ||||
| Shares Owned By Insiders | 61.24 % | ||||
| Shares Owned By Institutions | 2.14 % | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 6.62 X | ||||
| Revenue | 1.75 B | ||||
| Gross Profit | 1.57 B | ||||
| EBITDA | 506.9 M | ||||
| Net Income | 465.92 M | ||||
| Total Debt | 4.86 M | ||||
| Book Value Per Share | 23.20 X | ||||
| Cash Flow From Operations | 677.01 M | ||||
| Earnings Per Share | 0.81 X | ||||
| Target Price | 40.0 | ||||
| Number Of Employees | 1.73 K | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 11.38 B | ||||
| Total Asset | 10.08 B | ||||
| Retained Earnings | 4.04 B | ||||
| Working Capital | 6.89 B | ||||
| Annual Yield | 0.03 % | ||||
| Net Asset | 10.08 B | ||||
| Last Dividend Paid | 0.8 |
About Liaoning Chengda Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Liaoning Chengda Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Liaoning Chengda using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Liaoning Chengda Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Liaoning Stock
Liaoning Chengda financial ratios help investors to determine whether Liaoning Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Liaoning with respect to the benefits of owning Liaoning Chengda security.